Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab

Abstract

This study provides Class IV evidence that rituximab has an equal or superior effect in reducing inflammatory activity in RRMS measured by MRI and CSF-NFL compared to first-line injectables during the first year after treatment shift.